2011
DOI: 10.1177/1066896911418643
|View full text |Cite
|
Sign up to set email alerts
|

Pseudoangiomatous Stromal Hyperplasia (PASH) of the Breast

Abstract: Based on these results, extensive sampling of biopsy specimen with PASH and appropriate clinical and radiologic follow-up is recommended.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
63
2
9

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(75 citation statements)
references
References 20 publications
(35 reference statements)
1
63
2
9
Order By: Relevance
“…57 The detailed clinical presentation, morphology, immunophenotype, and behavior of PASH were described in several large studies. [58][59][60] In the skin, PASH was recognized in 2005. 11 Like gestational gynecomastia, PASH appears to represent an abnormal proliferative stromal response to estrogen, which can be blocked by Tamoxifen.…”
Section: Discussionmentioning
confidence: 99%
“…57 The detailed clinical presentation, morphology, immunophenotype, and behavior of PASH were described in several large studies. [58][59][60] In the skin, PASH was recognized in 2005. 11 Like gestational gynecomastia, PASH appears to represent an abnormal proliferative stromal response to estrogen, which can be blocked by Tamoxifen.…”
Section: Discussionmentioning
confidence: 99%
“…Excisional biopsy was deemed too high a risk for causing damage to the breast bud due to the inability to distinguish it from the tumour, therefore, an incisional biopsy was the treatment of choice 11. PASH lesions are not known to metastasise, however, local recurrences have been described; rates ranging from 0% to 22% and largely attributed to incomplete excision or presence of unknown multifocal lesions 3 12–14. PASH is not thought to be a premalignant condition and does not confer any increased risk for malignancy as evidenced by a large retrospective case series of 579 cases of biopsy-proven PASHs 15.…”
Section: Discussionmentioning
confidence: 99%
“…Pathologically the distinctive features are lack of true vessels and no cytological pleomorphism in PASH. The lining cells in PASH are not endothelial in origin; on immunostaining they show variable CD34 expression and are negative for other endothelial markers (eg CD31, factor VIII, ERG) 3. Angiosarcoma, however, would be expected to have positive expression of CD34, CD31, ERG and factor VIII 4…”
Section: Differential Diagnosismentioning
confidence: 99%
“…The histopathological differential diagnosis of PASH includes benign and malignant lesions of the breast, such as myofibroblastoma and low grade angiosarcoma (3,10). Myofibroblastoma is also a well-circumscribed, slowly growing, nodular lesion that is generally located in the subareolar region.…”
Section: Discussionmentioning
confidence: 99%
“…We mostly characterize PASH as an incidental finding accompanying several benign or malignant lesions of breast while evaluating the surgical excision specimens microscopically. Occasionally, it may comprise a mass and therefore present as a palpable nodule clinically (3). It has been reported as either a rapidly enlarging nodule suspicious of malignancy or direct transformation to malignancy in single case reports (4,5).…”
Section: Introductionmentioning
confidence: 99%